Literature DB >> 3316389

Differential expression of the c-myb proto-oncogene marks the pre-B cell/B cell junction in murine B lymphoid tumors.

T P Bender1, W M Kuehl.   

Abstract

A series of murine B lymphoid tumor cell lines which are representative of the pre-B cell, immature and mature B cell, and plasma cell stages of B cell development have been examined for expression of c-myb proto-oncogene mRNA. The pre-B cell lymphoma cell lines express equivalent high steady state levels of c-myb mRNA. In contrast, the B cell lymphoma and plasmacytoma cell lines express steady state c-myb mRNA at levels which are 0.005 to 0.1 times that of the pre-B cell lymphoma lines. These results correlate high levels of c-myb mRNA expression with the pre-B cell stage of development. Subclones of the 1881 pre-B cell lymphoma which express K light chain and are surface IgM-positive as well as two types of hybrid B lymphoid cell lines have been used to demonstrate that surface immunoglobulin expression is not sufficient to result in the down-regulation of c-myb mRNA levels or changes in the expression N-myc mRNA, lambda 5 mRNA, or the BP-1 surface antigen which are markers of the pre-B cell stage of development. Thus, changes in the expression of genes which are independent of immunoglobulin expression are associated with transition from the pre-B cell to the immature B cell stage of development.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3316389

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

1.  c-Myb binds to a sequence in the proximal region of the RAG-2 promoter and is essential for promoter activity in T-lineage cells.

Authors:  Q F Wang; J Lauring; M S Schlissel
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

2.  Transcriptional down-regulation of N-myc expression during B-cell development.

Authors:  R K Smith; K Zimmerman; G D Yancopoulos; A Ma; F W Alt
Journal:  Mol Cell Biol       Date:  1992-04       Impact factor: 4.272

3.  Isolation of coordinately regulated genes that are expressed in discrete stages of B-cell development.

Authors:  G D Yancopoulos; E M Oltz; G Rathbun; J E Berman; R K Smith; R D Lansford; P Rothman; A Okada; G Lee; M Morrow
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

4.  The cellular oncogene c-myb can interact synergistically with the Epstein-Barr virus BZLF1 transactivator in lymphoid cells.

Authors:  S C Kenney; E Holley-Guthrie; E B Quinlivan; D Gutsch; Q Zhang; T Bender; J F Giot; A Sergeant
Journal:  Mol Cell Biol       Date:  1992-01       Impact factor: 4.272

5.  c-Myb promotes the survival of CD4+CD8+ double-positive thymocytes through upregulation of Bcl-xL.

Authors:  Joan Yuan; Rowena B Crittenden; Timothy P Bender
Journal:  J Immunol       Date:  2010-02-08       Impact factor: 5.422

6.  RAV-1 insertional mutagenesis: disruption of the c-myb locus and development of avian B-cell lymphomas.

Authors:  E Pizer; E H Humphries
Journal:  J Virol       Date:  1989-04       Impact factor: 5.103

7.  Only the DNA binding and transactivation domains of c-Myb are required to block terminal differentiation of murine erythroleukemia cells.

Authors:  A E Cuddihy; L A Brents; N Aziz; T P Bender; W M Kuehl
Journal:  Mol Cell Biol       Date:  1993-06       Impact factor: 4.272

8.  Mechanism of c-myc regulation by c-Myb in different cell lineages.

Authors:  J P Cogswell; P C Cogswell; W M Kuehl; A M Cuddihy; T M Bender; U Engelke; K B Marcu; J P Ting
Journal:  Mol Cell Biol       Date:  1993-05       Impact factor: 4.272

9.  Activation of the c-myb locus is insufficient for the rapid induction of disseminated avian B-cell lymphoma.

Authors:  E S Pizer; T W Baba; E H Humphries
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

10.  Application for PCR technology to subtractive cDNA cloning: identification of genes expressed specifically in murine plasmacytoma cells.

Authors:  C Timblin; J Battey; W M Kuehl
Journal:  Nucleic Acids Res       Date:  1990-03-25       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.